Wealthcare Advisory Partners LLC Acquires Shares of 1,656 Eli Lilly and Co (LLY)

Wealthcare Advisory Partners LLC acquired a new stake in Eli Lilly and Co (NYSE:LLY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,656 shares of the company’s stock, valued at approximately $142,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2.1% in the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after purchasing an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Eli Lilly and by 16.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after purchasing an additional 1,503,918 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after purchasing an additional 237,619 shares during the last quarter. Finally, Dodge & Cox boosted its stake in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after purchasing an additional 5,964,955 shares during the last quarter. Hedge funds and other institutional investors own 76.30% of the company’s stock.

Eli Lilly and Co (LLY) opened at $85.52 on Friday. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09. The firm has a market cap of $94,170.00, a P/E ratio of 40.72, a P/E/G ratio of 1.59 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company posted $0.88 EPS. analysts forecast that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.63%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is 99.05%.

In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares in the company, valued at approximately $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock worth $22,041,236 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Several research analysts have recently issued reports on LLY shares. Jefferies Group reaffirmed a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Wednesday, November 1st. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $90.25.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3126548/wealthcare-advisory-partners-llc-acquires-shares-of-1656-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.